# Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma

> **NCT05327738** · PHASE2 · WITHDRAWN · sponsor: **OHSU Knight Cancer Institute**

## Conditions studied

- BCLC Stage B Hepatocellular Carcinoma
- BCLC Stage C Hepatocellular Carcinoma
- Locally Advanced Hepatocellular Carcinoma
- Recurrent Hepatocellular Carcinoma
- Unresectable Hepatocellular Carcinoma

## Interventions

- **BIOLOGICAL:** Atezolizumab
- **PROCEDURE:** Biopsy
- **DRUG:** Cabozantinib S-malate
- **RADIATION:** Yttrium Y 90 Glass Microspheres

## Key facts

- **NCT ID:** NCT05327738
- **Lead sponsor:** OHSU Knight Cancer Institute
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2022-12-10
- **Primary completion:** 2027-12-04
- **Final completion:** 2027-12-04
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Due to inadequate funding. This trial may open as a new clinical trial at a later date, pending drug approval.
- **Last updated:** 2022-12-14

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05327738

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05327738, "Yttrium Y 90 Glass Microspheres, Atezolizumab, and Cabozantinib for the Treatment of Unresectable or Locally Advanced Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT05327738. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*